| KRYS Stock | | | USD 186.60 4.31 2.36% |
Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Retained Earnings Total Equity and its Total Current Liabilities accounts. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in manufacturing.
For more information on how to buy Krystal Stock please use our
How to Invest in Krystal Biotech guide.
Retained Earnings Total Equity vs Total Current Liabilities
Retained Earnings Total Equity vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Krystal Biotech Retained Earnings Total Equity account and
Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between Krystal Biotech's Retained Earnings Total Equity and Total Current Liabilities is -0.97. Overlapping area represents the amount of variation of Retained Earnings Total Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Retained Earnings Total Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings Total Equity of Krystal Biotech are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Retained Earnings Total Equity i.e., Krystal Biotech's Retained Earnings Total Equity and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.97 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Retained Earnings Total Equity
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.
Total Current Liabilities
Total Current Liabilities is an item on Krystal Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Krystal Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in manufacturing.
For more information on how to buy Krystal Stock please use our
How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's
Selling General Administrative is comparatively stable compared to the past year.
Tax Provision is likely to gain to about 2.1
M in 2024, whereas
Issuance Of Capital Stock is likely to drop slightly above 164
M in 2024.
Krystal Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Krystal Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krystal Biotech fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to
measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to
predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.